|
|
|
Dear all,
It is with great pleasure we are launching the Episealer® Patellofemoral System in the global orthopaedic markets. We are starting with the US market, and we received FDA clearance late last year. Our work of establishing a US distribution network has progressed well during the year, and we look forward to the next steps in this very exciting market. In other markets, we are welcoming more and more surgeons as customers, and our personalised solutions are gaining traction worldwide.
Below, you will find several highlights from the last months – and do not hesitate to reach out to an Episurf representative should you want to learn more.
Sincerely yours,
Pål Ryfors
CEO, Episurf Medical
|
|
EPISEALER® PATELLOFEMORAL SYSTEM
|
In the spring of 2023, Episurf started introducing the Episealer® Patellofemoral system, an implant system with two opposing implants intended for patients with osteoarthritis limited to the distal patellofemoral joint in the knee. It is based on Episurf Medical’s proprietary personalised implant technology.
Episurf has received 510(k) clearance from the US Food and Drug Administration (FDA) for the Episealer® Patellofemoral System. The system is also available in India, Australia and in the United Arab Emirates. We are looking forward to launching the product in additional countries shortly.
Link to product information >>
|
|
|
HEALTH ECONOMIC STUDY PUBLISHED IN THE JOURNAL OF ISAKOS
|
The results of a cost-benefit study, which focuses on the health economic aspects surrounding treatment with the Episealer® knee implant, has been published in the Journal of ISAKOS. The manuscript, titled "Individualized metal implants for focal cartilage lesions in the knee can be cost effective: A simulation on 47-year-olds in a Swedish setting" by L. Bernfort et al. assesses the cost-benefit of the Episealer® knee implant for the treatment of delimited cartilage damage in the knee joint compared to the biological treatment method microfracturing, which is the standard procedure in Sweden. The manuscript concludes that the implant Episealer® is a cost-effective treatment option for patients in their 40s, compared with microfracturing.
Link to publication >>
|
|
|
FIRST EPISEALER® TALUS SURGERY IN INDIA
|
On April 15th, Dr Rajesh Simon, Senior Consultant and Foot & Ankle Surgeon at VPS Lakeshore Hospital and current President of IFAS along with Prof. Niek van Dijk performed the first Episealer® Talus surgery in India. The surgery was performed at a live surgical workshop which was organised in collaboration between VPS Lakeshore Hospital and the Indian Foot Ankle Society (IFAS).
Dr Rajesh Simon expressed after the surgery that “Using the Epiguide during the surgery increases the precision of the surgical procedure and there are no superior treatment of osteochondral defects available”.
National media reported from the live surgery event and the article is available on-line.
Link to article >>
|
|
|
EVENT CALENDAR, EPISURF MEDICAL 2023
|
|
|
PRESS RELEASES
|
|
Please click on the images/text below to access the most relevant recent press releases:
|
|
|
|
WANT TO STAY UPDATED WITH THE LATEST NEWS FROM EPISURF?
|
|
There are many options for those who want to stay updated with the latest Episurf news. You are welcome to follow the links below to sign up for our press releases and newsletters. Or follow us on social media!
|
|
|
|
|
|
|
|
Episurf Medical has a Privacy Policy in line with the European General Data Protection Regulation (GDPR).
Read more about our policy here>>
If you no longer wish to receive our newsletter, please click the 'unsubscribe' link at the bottom of this newsletter.
|
|
